1. Overview of Licensing in Regenerative Medicine

Regenerative medicine involves therapies that repair, replace, or regenerate damaged tissues or organs, often using stem cells, gene editing, or tissue engineering. Because of the high innovation and cost, patents play a critical role in protecting these inventions.

Licensing is the legal mechanism allowing patent holders to permit others to use their inventions under agreed terms, often for royalties or upfront fees.

Licensing regenerative medicine patents faces several challenges:

Patent eligibility: Are stem cells, genes, or engineered tissues patentable?

Scope of claims: Broad claims risk invalidation, narrow claims limit licensing opportunities.

Ethical considerations: Some jurisdictions limit patenting human embryos or embryonic stem cells.

Freedom to operate: Licensees must ensure they do not infringe other patents.

2. Key Legal Issues in Licensing Regenerative Medicine Patents

Patent eligibility of biological materials

Scope and enforceability of claims

Moral and ethical limits (human embryonic stem cells)

Compulsory licensing in case of public health emergencies

Collaborative licensing in academia-industry partnerships

3. Important Case Laws

Here’s a deep dive into more than five landmark cases relevant to licensing regenerative medicine patents:

Case 1: Diamond v. Chakrabarty (1980, U.S.)

Facts:

An Indian-born scientist, Ananda Chakrabarty, genetically engineered a bacterium capable of breaking down crude oil.

The patent office initially rejected the patent on the grounds that living organisms cannot be patented.

Decision:

The U.S. Supreme Court ruled that a human-made genetically modified organism is patentable, as it is a “manufacture” or “composition of matter” under U.S. patent law.

Impact on Licensing:

This opened the door for patents on genetically engineered cells and tissues in regenerative medicine.

Licensing of such patents became possible, allowing biotech firms to commercialize genetically engineered therapies.

Case 2: Harvard College v. Canada (Commissioner of Patents) (2002, Canada)

Facts:

Harvard patented a method for isolating and purifying human embryonic stem cells.

The Canadian patent office initially rejected it citing ethical concerns.

Decision:

The Supreme Court of Canada emphasized that while ethical concerns are important, the patentability of stem cell methods is valid if the invention is novel, non-obvious, and useful.

Impact on Licensing:

Clarified that regenerative medicine patents, including those involving embryonic stem cells, can be licensed under Canadian law if they meet patent criteria.

Case 3: Myriad Genetics, Inc. v. Association for Molecular Pathology (2013, U.S.)

Facts:

Myriad Genetics patented isolated BRCA1 and BRCA2 genes, linked to breast and ovarian cancer.

The patents blocked other companies from developing diagnostic tests.

Decision:

The Supreme Court ruled that naturally occurring DNA sequences cannot be patented, but complementary DNA (cDNA) is patentable because it is synthetically created.

Impact on Licensing:

Licensing of regenerative medicine patents must distinguish between natural biological materials (unpatentable) and engineered or modified materials (patentable).

This affects royalty negotiations and freedom-to-operate analyses.

Case 4: Association for Molecular Pathology v. Myriad Genetics, U.S. District Court (2009, U.S.)

Facts:

Same context as above but initially in lower courts.

Plaintiffs argued Myriad’s patents limited research access.

Decision:

The court invalidated claims on isolated genes, emphasizing that scientists cannot be blocked from studying natural DNA sequences.

Impact on Licensing:

Encouraged research-use licenses, a common mechanism in regenerative medicine to allow academic research while protecting commercial rights.

Case 5: Regeneron Pharmaceuticals v. Kymab (2018, U.K.)

Facts:

Regeneron and Kymab had disputes over patents involving antibody engineering in regenerative therapies.

The disagreement centered on whether Kymab’s patents blocked Regeneron’s licensing deals.

Decision:

U.K. High Court emphasized careful drafting of patent claims, particularly in biotech, to ensure licensing agreements are enforceable and clear.

Impact on Licensing:

Highlighted the importance of freedom-to-operate analysis in regenerative medicine licensing.

Reinforced the need for cross-licensing agreements in collaborative biotech research.

Case 6: International Stem Cell Corporation v. California Institute for Regenerative Medicine (2014, U.S.)

Facts:

Stem cell patent disputes regarding parthenogenetic stem cells (from unfertilized eggs).

International Stem Cell Corp sued for patent infringement.

Decision:

Courts recognized the patentability of parthenogenetic stem cells, noting they are human-made and distinct from naturally occurring cells.

Impact on Licensing:

Reinforced that novel regenerative medicine inventions, even if biologically derived, can be licensed commercially.

Case 7: Eli Lilly & Co. v. Genentech, Inc. (2001, U.S.)

Facts:

Dispute over patents for recombinant DNA technology in therapeutic proteins.

Eli Lilly alleged that Genentech’s products infringed their patents.

Decision:

Court emphasized narrow claim interpretation in biotechnology patents.

Licensing agreements must explicitly define scope of use, species, and cell types to avoid infringement.

Impact on Licensing:

Demonstrates the importance of carefully drafted licenses in regenerative medicine, particularly when multiple patents cover overlapping technologies.

4. Licensing Models in Regenerative Medicine

Based on these cases, biotech companies typically use:

Exclusive Licensing – Licensee gets sole rights, common for commercialization.

Non-Exclusive Licensing – Multiple parties can use the patent, common for research-use.

Cross-Licensing – Parties exchange rights to each other’s patents to reduce litigation risk.

Royalty-Based Agreements – Payments based on sales, especially for high-cost therapies.

Milestone Payments – Upfront fees plus staged payments as development progresses.

5. Key Takeaways

Regenerative medicine patents must be novel, non-obvious, and useful; natural materials alone may not qualify (Myriad).

Engineering or synthetic modifications make patents licenseable (Chakrabarty, International Stem Cell Corp).

Licensing requires careful drafting, especially regarding scope, species, cell types, and research use (Regeneron, Eli Lilly).

Ethical and jurisdictional concerns matter but do not automatically block patents (Harvard stem cells).

Freedom-to-operate and cross-licensing are essential in a crowded biotech patent landscape.